Loading
Adding a second HER2 antibody, pertuzumab, to a year of trastuzumab after surgery reduced recurrences modestly in early HER2-positive breast cancer, with the gain concentrated in women with lymph node involvement.
Phase 3 placebo-controlled trial of 4,805 patients with operable HER2-positive breast cancer randomised to chemotherapy plus trastuzumab with pertuzumab or placebo for one year.
Three-year invasive disease-free survival was 94.1 percent with pertuzumab against 93.2 percent with placebo (hazard ratio 0.81); in node-positive disease the absolute gain grew to 4.5 percent at six years, with no benefit seen in node-negative disease. Diarrhoea was the main added toxicity.
Dual HER2 blockade after surgery is reserved for node-positive or otherwise higher-risk disease, where the benefit is real but small; node-negative patients can be spared the extra drug.
Shares Early HER2-positive breast cancer, Trastuzumab, New England Journal of Medicine.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab.
Shares APHINITY, Pertuzumab, Trastuzumab.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab.
Shares Pertuzumab, Trastuzumab.
Shares Pertuzumab, Trastuzumab.